Review: Interstitial Lung Disease Associated with Systemic Sclerosis and Idiopathic Pulmonary Fibrosis: How Similar and Distinct?

Overview

Journal Arthritis Rheumatol

Publisher Wiley

Specialty Rheumatology

Date 2014 May 20

PMID 24838199

Citations 94

Authors

Erica L Herzog

Aditi Mathur

Andrew M Tager

Carol Feghali-Bostwick

Frank Schneider

John Varga

Affiliations

Soon will be listed here.

Citing Articles

Explainable fully automated CT scoring of interstitial lung disease for patients suspected of systemic sclerosis by cascaded regression neural networks and its comparison with experts.

Jia J, Hernandez-Giron I, Schouffoer A, de Vries-Bouwstra J, Ninaber M, Korving J Sci Rep. 2024; 14(1):26666.

PMID: 39496802 PMC: 11535448. DOI: 10.1038/s41598-024-78393-4.

Parvovirus B19 in Rheumatic Diseases.

Arvia R, Stincarelli M, Manaresi E, Gallinella G, Zakrzewska K Microorganisms. 2024; 12(8).

PMID: 39203550 PMC: 11357344. DOI: 10.3390/microorganisms12081708.

Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.

Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F Am J Respir Crit Care Med. 2024; .

PMID: 39189851 PMC: 11755360. DOI: 10.1164/rccm.202401-0065OC.

Macrophages as determinants and regulators of systemic sclerosis-related interstitial lung disease.

Lee S, Huang C, Oyang Y, Huang H, Juan H J Transl Med. 2024; 22(1):600.

PMID: 38937794 PMC: 11212242. DOI: 10.1186/s12967-024-05403-4.

Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates.

Prajjwal P, Marsool M, Yadav V, Kanagala R, Reddy Y, John J Health Sci Rep. 2024; 7(4):e2072.

PMID: 38660003 PMC: 11040569. DOI: 10.1002/hsr2.2072.

References

Gerbino A, Goss C, Molitor J . Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2007; 133(2):455-60. DOI: 10.1378/chest.06-2861. View

Murray L, Rubinowitz A, Herzog E . Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease?. Curr Opin Rheumatol. 2012; 24(6):656-62. DOI: 10.1097/BOR.0b013e3283588de4. View

Fischer A, Brown K, du Bois R, Frankel S, Cosgrove G, Fernandez-Perez E . Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013; 40(5):640-6. PMC: 3676865. DOI: 10.3899/jrheum.121043. View

Zamora A, Wolters P, Collard H, Connolly M, Elicker B, Webb W . Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2007; 102(1):150-5. DOI: 10.1016/j.rmed.2007.07.021. View

Desai S, Veeraraghavan S, Hansell D, Nikolakopolou A, Goh N, Nicholson A . CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004; 232(2):560-7. DOI: 10.1148/radiol.2322031223. View

Peng X, Mathai S, Murray L, Russell T, Reilkoff R, Chen Q . Local apoptosis promotes collagen production by monocyte-derived cells in transforming growth factor β1-induced lung fibrosis. Fibrogenesis Tissue Repair. 2011; 4(1):12. PMC: 3123188. DOI: 10.1186/1755-1536-4-12. View

Nihtyanova S, Schreiber B, Ong V, Rosenberg D, Moinzadeh P, Coghlan J . Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014; 66(6):1625-35. DOI: 10.1002/art.38390. View

Truchetet M, Brembilla N, Montanari E, Allanore Y, Chizzolini C . Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther. 2011; 13(5):R166. PMC: 3308100. DOI: 10.1186/ar3486. View

Tashkin D, Elashoff R, Clements P, Roth M, Furst D, Silver R . Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007; 176(10):1026-34. PMC: 2078679. DOI: 10.1164/rccm.200702-326OC. View

10.

Pochetuhen K, Luzina I, Lockatell V, Choi J, Todd N, Atamas S . Complex regulation of pulmonary inflammation and fibrosis by CCL18. Am J Pathol. 2007; 171(2):428-37. PMC: 1934523. DOI: 10.2353/ajpath.2007.061167. View

11.

ODwyer D, Armstrong M, Trujillo G, Cooke G, Keane M, Fallon P . The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2013; 188(12):1442-50. DOI: 10.1164/rccm.201304-0760OC. View

12.

Nadashkevich O, Davis P, Fritzler M, Kovalenko W . A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2005; 25(2):205-12. DOI: 10.1007/s10067-005-1157-y. View

13.

Spiera R, Gordon J, Mersten J, Magro C, Mehta M, Wildman H . Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011; 70(6):1003-9. PMC: 3086082. DOI: 10.1136/ard.2010.143974. View

14.

Christmann R, Mathes A, Affandi A, Padilla C, Nazari B, Bujor A . Thymic stromal lymphopoietin is up-regulated in the skin of patients with systemic sclerosis and induces profibrotic genes and intracellular signaling that overlap with those induced by interleukin-13 and transforming growth factor β. Arthritis Rheum. 2013; 65(5):1335-46. PMC: 4437575. DOI: 10.1002/art.37859. View

15.

Peljto A, Steele M, Fingerlin T, Hinchcliff M, Murphy E, Podlusky S . The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest. 2012; 142(6):1584-1588. PMC: 3515031. DOI: 10.1378/chest.12-0110. View

16.

Khanna D, Saggar R, Mayes M, Abtin F, Clements P, Maranian P . A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011; 63(11):3540-6. PMC: 3205223. DOI: 10.1002/art.30548. View

17.

Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P . Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 179(12):1121-30. DOI: 10.1164/rccm.200812-1936OC. View

18.

Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen H . High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353(21):2229-42. DOI: 10.1056/NEJMoa042976. View

19.

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

20.

Solomon J, Olson A, Fischer A, Bull T, Brown K, Raghu G . Scleroderma lung disease. Eur Respir Rev. 2013; 22(127):6-19. PMC: 4103193. DOI: 10.1183/09059180.00005512. View